As of Nov 19, 2026, 2 of 2 active firms rate INBX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INBX EPS & revenue forecast
EPS · NEXT QUARTER
$-2.37
Range $-2.52 – $-2.22 · 2 analysts · +10% YoY
Next period, 2 analysts expect Inhibrx Biosciences, Inc. to earn $-2.37 a share (range $-2.52 – $-2.22), versus $-2.15 a year earlier. Full-year consensus is $-9.26, growing to $-8.76 the year after.
REVENUE · NEXT QUARTER
$1.2M
Range $0 – $2.4M · 2 analysts
Revenue is expected to reach $1.2M (range $0 – $2.4M). Full-year consensus is $0, rising to $36.1M next year.
Top analysts covering Inhibrx Biosciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INBX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$245.00+255.3% to target
Overall win rate
42%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #489
Neutral
No targeton INBX
Overall win rate
29%
+ Follow
#3
DA
Dara Azar
Stifel Nicolaus
Buy
$150.00+117.5% to target
Coverage
—
+ Follow
INBX stock forecast FAQ
What is INBX's average 12-month price target?+
The 2 active firms with a live target average $197.50 for Inhibrx Biosciences, Inc. over the next 12 months, ranging from a $245.00 high to a $150.00 low, as of Nov 19, 2026.
Is INBX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for INBX?+
The Street-high target is $245.00 (HC Wainwright & Co.), and the Street-low is $150.00 (Stifel). The average of all 2 active-firm targets is $197.50.
How many active Wall Street firms cover INBX?+
2 active firms have a recognized rating on Inhibrx Biosciences, Inc. as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INBX?+
Among analysts who currently cover INBX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $245.00 target.
What is Inhibrx Biosciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-2.37 per share (range $-2.52 – $-2.22) across 2 analysts. Full-year EPS is projected at $-9.26, rising to $-8.76 the following year.
How much revenue is Inhibrx Biosciences, Inc. expected to report next quarter?+
Consensus revenue is $1.2M (range $0 – $2.4M). Full-year revenue is projected at $0, growing to $36.1M next year.
Have analysts been upgrading or downgrading INBX lately?+
As of Nov 19, 2026, 2 of 2 active firms rate INBX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INBX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.